Capricor Therapeutics, Inc. Class Action Lawsuit - CAPR

Capricor Therapeutics, Inc.
NASDAQ: CAPR

Affected CAPR Investor Summary

- **Who:** Capricor Therapeutics, Inc. (NASDAQ: CAPR)
- **What:** Securities fraud class action lawsuit filed
- **Class Period:** December 17, 2025 through July 26, 2026
- **Deadline to Seek Lead Plaintiff Status:** September 28, 2026
- **Key Lawsuit Allegations:** Material misstatements and/or omissions concerning the company's lead product candidates statistical analysis plan and FDA compliance
- **Investor Action:** Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options

---

The *Capricor Therapeutics, Inc.* class action lawsuit was filed on behalf of those who purchased or otherwise acquired *Capricor Therapeutics, Inc.* ("*Capricor*") (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"). Captioned *Darren Ngasseu Nkamga v. Capricor Therapeutics, Inc.,* No. 26-cv-04385 (S.D. Cal.), the *Capricor* class action lawsuit alleges that *Capricor* and/or certain of its officers and/or directors violated federal securities laws by making false or misleading statements and/or omitted to disclose material information.

If you lost money as a result of your *Capricor* investment and want to find out more about this action and your rights, fill out the form on this page or contact attorney Jonathan Naji, Esq. of KTMC by calling (484) 270-1453 or via e-mail at info@ktmc.com. Lead plaintiff motions must be filed with the court no later than September 28, 2026.

COMPLAINT ALLEGATION SUMMARY:

Capricor is a biotechnology company focused on the development of cell and exosome-based therapeutics for the treatment of a rare genetic disorder characterized by progressive muscle degeneration and premature death. Its lead product candidate is Deramiocel, a cell therapy to address cardiac and skeletal muscle complications associated with Duchenne muscular dystrophy.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) *Capricor* had adopted changes to the pre-specified statistical analysis plan used to analyze Deramiocel clinical data; (2) the FDA had not agreed to these changes prior to *Capricor* resubmitting the Biologics License Application ("BLA"); (3) the absence of agreement created significant risk that the FDA could conclude that the clinical results of Deramiocel did not provide substantial evidence of its effectiveness and risking its chances for approval; and (4) as a result of the foregoing, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHY DID CAPRICOR'S STOCK DROP?
On July 27, 2026, the FDA released briefing documents ahead of its July 29 advisory committee meeting for Deramiocel's BLA. The briefing documents revealed that *Capricor* had made changes to the pre-specified statistical analysis plan and failed to submit the final version to the FDA for review "prior to BLA submission and was not discussed and consequently not agreed upon." The FDA went on to disagree with the changes, stating that the **"**FDA does not consider the conversion of raw change to percent change and then back to raw change to have been scientifically justified, as it adds complexity and reduces accuracy." The briefing documents continued, detailing that "the benefit-risk assessment for deramiocel appears unfavorable in the absence of evidence of effectiveness." On this news, the price of *Capricor* stock fell 64%.

THE LEAD PLAINTIFF PROCESS:
The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired *Capricor* securities during the Class Period to seek appointment as lead plaintiff in the *Capricor* class action lawsuit. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and

California. KTMC has recovered over $25 billion for our clients and the classes they represent.